Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

被引：0

作者：

Stopeck, Alison T. ^{[1
]}

Unger, Joseph M. ^{[2
]}

Rimsza, Lisa M. ^{[3
]}

Farnsworth, Brent ^{[3
]}

LeBlanc, Michael ^{[2
]}

Iannone, Maria ^{[1
]}

Fisher, Richard I. ^{[4
]}

Miller, Thomas P. ^{[1
]}

机构：

[1] Arizona Canc Ctr, Tucson, AZ USA

[2] SW Oncol Grp, Seattle, WA USA

[3] Univ Arizona, Tucson, AZ USA

[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：260 / 261

页数：2

共 50 条

[1] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
Candelaria, Myrna
Duenas-Gonzalez, Alfonso
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[2] A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Stopeck, Alison T.
Unger, Joseph M.
Rimsza, Lisa M.
LeBlanc, Michael
Farnsworth, Brent
Iannone, Maria
Glenn, Martha J.
Fisher, Richard I.
Miller, Thomas P.
BLOOD, 2012, 120 (06) : 1210 - 1217
[3] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
Wöhrer, S
Püspök, A
Drach, J
Hejna, M
Chott, A
Raderer, M
ANNALS OF ONCOLOGY, 2004, 15 (07) : 1086 - 1090
[4] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
Dietrich, S.
Tilly, H.
Morschhauser, F.
Sehn, L. H.
Friedberg, J.
Trneny, M.
Sharman, J. P.
Herbaux, C.
Burke, J. M.
Matasar, M.
Rai, S.
Izutsu, K.
Mehta-Shah, N.
Oberic, L.
Chauchet, A.
Jurczak, W.
Song, Y.
Greil, R.
Mykhalska, L.
Burgues, J. M. B.
Cheung, M. C.
Pinto, A.
Shin, H-J
Hapgood, G.
Munhoz, E.
Abrisqueta, P.
Gau, J-P
Hirata, J.
Jiang, Y.
Yan, M.
Lee, C.
Flowers, C.
Salles, G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
[5] ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
Johnson, Peter W. M.
Caddy, Joshua
Cumin, Tom
Merton, Bridgen
Maishman, Tom
Galanopoulou, Angelic
Griffiths, Gareth
Davies, Andrew
CANCER RESEARCH, 2018, 78 (13)
[6] Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lymphoma
Aguiar Bujanda, D.
Cabrera Suarez, M. A.
Llorca Martinez, I.
Bohn Sarmiento, U.
Saura Grau, S.
Rodriguez Franco, C.
Aguiar Morales, J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial
Watanabe, Takashi
Morishima, Yasuo
Shibata, Taro
Maseki, Nobuo
Kinoshita, Tomohiro
Suzuki, Takayo
Yamaguchi, Motoko
Ando, Kiyoshi
Ogura, Michinori
Taniwaki, Masafumi
Uike, Naokuni
Takeuchi, Kengo
Nawano, Shigeru
Terauchi, Takashi
Tsukasaki, Kunihiro
Hotta, Tomomitsu
Tobinai, Kensei
BLOOD, 2010, 116 (21) : 193 - 193
[8] Markers of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab
Badari, Ambuga R.
Abu Zaid, Mohammad
Unger, Joseph M.
Rimsza, Lisa M.
Marron, Marilyn
Fisher, Richard I.
Miller, Thomas P.
Stopeck, Alison
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[9] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
Dietrich, Sascha
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yu Qin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Salles, Gilles
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
[10] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Flowers, Christopher
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359

← 1 2 3 4 5 →